Immune checkpoint inhibitors combined with tyrosine kinase inhibitors is the treatment option of previously treated advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration

Detalles Bibliográficos
Autores principales: Yang, Xiaobo, Zhu, Chengpei, Zhao, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641038/
https://www.ncbi.nlm.nih.gov/pubmed/36386458
http://dx.doi.org/10.21037/tlcr-22-522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641038/
https://www.ncbi.nlm.nih.gov/pubmed/36386458
http://dx.doi.org/10.21037/tlcr-22-522

Ejemplares similares